Results of Operations and Financial Condition
Show detailsHide details
2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
Maxcyte, Inc.
A maker of electroporation instruments and technology that help scientists slip genetic material like mRNA and DNA into living cells — a key step in building cell and gene therapies and vaccines. Its Flow Electroporation platform is used by biopharma companies and researchers to engineer cells for treating disease. Founded in 1999 in Gaithersburg, Maryland, the company's name blends "maximum" and "cyte" (the Greek root for cell), reflecting its goal of getting the most out of every engineered cell.
2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
5.07 Submission of Matters to a Vote of Security Holders
3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits